Impact Biomedical (IBO) Total Non-Current Liabilities (2022 - 2023)
Impact Biomedical's (IBO) quarterly Total Non-Current Liabilities came in at $15.5 million in Q3 2023, up 12.1% quarter-over-quarter from $13.8 million in Q4 2022.
Powered by 
Analysis
Impact Biomedical (IBO) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Impact Biomedical (IBO) has reported Total Non-Current Liabilities for 2 consecutive years, with $15.5 million the latest figure, recorded in Q3 2023.
- For the quarter ending Q3 2023, Total Non-Current Liabilities changed N/A year-over-year to $15.5 million; the trailing twelve-month figure through Sep 2023 stood at $15.5 million (changed N/A YoY), and the FY2022 full-year result was $13.8 million, changed N/A from the prior year.
- Total Non-Current Liabilities climbed to $15.5 million in Q3 2023 per IBO's latest filing, from $13.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $15.5 million in Q3 2023 and bottomed at $13.8 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 | - |